Replies to post #27216 on Marker Therapeutics Inc (MRKR)

[guydiamond]

It means your (the patient's) natural immune system is joining in on the fight. They are seeing NEW t-cells that target antigens on the tumor that WERE NOT part of their therapy.

But, I think correlative means they aren't able to strictly attribute this effect to their therapy. Somebody correct me though; I'm not an expert on terminology and implications of biotech trial analyses.

[poods]

They are simply saying the product did what they had hoped. The infused cells propagated/expanded in the patient, but as or more importantly, those T-cells created an immune response that recruited other T-cells directed at other tumor associated antigen targets than were not included in the original infused T-cell product. "i.e. epitope/antigen spreading"

[Inoviorulez]

In other words, MultiTAA is equipped with peptides that target only 5 antigens on a tumor (cancer cells). However, MultiTAA has what is known asn an epitope spreading effect, meaning that the treatment from the company recruits other parts of the immune system to also target the tumor and to target the tumor with different antigen targets. That's important because tumors are heterogenous in nature, meaning they display multiple antigens, and not only that but they are always changing/adapting antigens. Therefore, epitope spreading takes care of eliminating cancer cells where otherwise MultiTAA wouldn't get to target.